Meeting Brochure and registration form      SMDM Homepage

Wednesday, 18 October 2006


Sarah C. Kobrin, PhD, MPH, Neeraj Arora, PhD, Paul K. J. Han, MD, MA, MPH, and Helen I. Meissner, PhD. National Cancer Institute, Bethesda, MD

Purpose: To examine the types of discussions men have with health care providers prior to getting a PSA (prostate-specific antigen) test.

Methods: Data were drawn from the National Cancer Institute's, nationally representative, 2005 Health Information National Trends Survey (n=5,394). Of the 778 men in the sample who were 50+ years old, never had prostate cancer, and had heard of a PSA test, we analyzed data from 607 (78%) who had received a PSA test and provided complete data. We assessed provider-patient communication about PSA testing by asking each respondent two questions: whether a provider had talked with him about PSA and the extent to which his provider encouraged him to ask questions/express concerns about PSA. Responses to these questions resulted in three “decision-making paths”: 1. Provider did not discuss PSA; 2. Provider discussed PSA but did not strongly encourage questions; 3. Provider discussed PSA and strongly encouraged questions.

Results: Men in our sample were largely white (88%), married (72%) and insured (96%); 44% had a college education; 32% had an annual income of at least $75K; 18% had a personal history of cancer other than prostate and 7% had family history of prostate cancer. Only 42% of respondents took the “best path” to a screening PSA test: discussion that included being strongly encouraged to ask questions. In fact, 12% had a PSA with no discussion at all; 46% had discussion without being strongly encouraged to ask questions. “Decision making path” was positively associated with income [p<0.05, chi sq (6) =13.86] and being married [p<0.01, chi sq (2) =11.56]. Education, race/ethnicity, insurance status, and both cancer history variables were not significant.

Conclusions: The majority of men who get a screening PSA test are doing so without a detailed discussion with a health care provider. National guidelines recommend providers facilitate informed decision-making by patients largely because current data do not support recommending for or against the PSA test; our nationally-representative data suggest these guidelines are not being followed. The possible longer-term consequences of having a screening PSA – and facing a cancer diagnosis, treatment choices, and side effects – without having a chance to talk about and question the plusses, minuses and alternatives, are unknown and warrant further investigation.

See more of Poster Session V
See more of The 28th Annual Meeting of the Society for Medical Decision Making (October 15-18, 2006)